Mastoid obliteration with S53P4 bioactive glass after canal wall down mastoidectomy: Preliminary results

Król, Bartłomiej; Cywka, Katarzyna B.; Skarżyńska, Magdalena Beata; Skarżyński, Piotr H.

doi:10.1016/j.amjoto.2020.102895

Cited by 13 publications

(20 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients who were previously excluded due to insufficient conditions for use of the BCI 601 can today undergo surgery using the BCI 602. The BCI 602 can be effectively applied in patients after a radical cavity operation or even after mastoid obliteration [ 26 , 27 ]. It can be applied more effectively and there is a better chance of long-term results [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Bonebridge BCI 602 active bone conductive implant in adults: efficacy and stability of audiological, surgical, and functional outcomes

Cywka

Skarżyński

Król

et al. 2022

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Purpose (1) To assess the effectiveness and safety of a bone-conduction implant, the Bonebridge BCI 602, in adults with conductive or mixed hearing loss. (2) To investigate whether the Bonebridge BCI 602 is at least as effective as the Bonebridge BCI 601 in such patients. Methods The study group included 42 adults who had either conductive or mixed hearing loss. All patients underwent Bonebridge BCI 602 implant surgery. Before and after implantation, pure-tone audiometry, speech recognition tests (in quiet and noise), and free-field audiometry were performed. Word recognition scores were evaluated using the Polish Monosyllabic Word Test. Speech reception thresholds in noise were assessed using the Polish Sentence Matrix Test. Subjective assessment of benefits was done using the APHAB (Abbreviated Profile of Hearing Aid Benefit) questionnaire. Results The APHAB questionnaire showed that difficulties in hearing decreased after BCI 602 implantation. Both word recognition in quiet and speech reception threshold in noise were significantly better after BCI 602 implantation and remained stable for at least 12 months. A significant advantage of the device is a reduced time for surgery while maintaining safety. In this study, the mean time for BCI 602 implantation was 28.3 min ± 9.4. Conclusions The second-generation Bonebridge BCI 602 implant is an effective hearing rehabilitation device for patients with conductive or mixed hearing loss. Patient satisfaction and audiological results confirm its efficacy and safety. Its new shape and dimensions allow it to be used in patients previously excluded due to insufficient or difficult anatomical conditions. The new BCI 602 implant is as effective as its predecessor, the BCI 601.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of the Bonebridge BCI 602 active bone conductive implant in adults: efficacy and stability of audiological, surgical, and functional outcomes

Cywka

Skarżyński

Król

et al. 2022

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

show abstract

“…Several studies reported on SSI after mastoid obliteration with BAG S53P4 in the management of chronic otitis media with and without cholesteatoma ( Bernardeschi, 2015 ; de Veij Mestdagh, 2017 ; Król, 2021 ; Leonard, 2021 ; Mishra, 2021 ; Sarin, 2012 ; Schimanski, 2015 ; Silvola, 2012 ; Sorour, 2018 ; Stoor, 2010 ; Vos, 2017 ) (see supplementary information, Table S2 ). The SSI rates in these studies vary from 0 to 2% and are lower compared to our rate of 12%, except for Silvola et al.…”

Section: Discussionmentioning

confidence: 99%

Postoperative surgical site infection in cholesteatoma surgery with and without mastoid obliteration, what can we learn?

et al. 2022

View full text Add to dashboard Cite

Introduction This study aims to describe the occurrence of postoperative complications related to cholesteatoma surgery and to determine factors influencing the most common complication, i.e. postoperative surgical site infection (SSI) in cases with and without mastoid obliteration. Materials and methods Retrospective analyses were performed on surgically treated cholesteatomas in our hospital between 2013 and 2019. Patient characteristics, peri- and postoperative management and complications were reviewed. The cases were divided into two groups based on whether mastoid obliteration was performed or not. Results A total of 336 cholesteatoma operations were performed, of which 248 cases received mastoid obliteration. In total 21 complications were observed, of which SSI was the most common (15/21). No difference in occurrence of any postoperative complication was seen between the obliteration and no-obliteration group ( p = 0.798), especially not in the number of SSI ( p = 0.520). Perioperative and/or postoperative prophylactic antibiotics were not associated to the development of an SSI in both groups. In the no-obliteration group a younger age (p = 0.015), as well as primary surgery ( p = 0.022) increased the risk for SSI. In the obliteration group the use of bioactive glass (BAG) S53P4 was identified as independent predictor of SSI ( p = 0.008, OR 5.940). Discussion SSI is the most common postoperative complication in cholesteatoma surgery. The causes of SSI are multifactorial, therefore further prospective research is needed to answer which factors can prevent the development of an SSI in cholesteatoma surgery.

show abstract

“…Therefore, expecting long-term results of the procedure in the case of mastoid obliteration is at this stage premature. Some authors even recommend, empirically, the use of antibiotic drops in combination with antifungal drops in the first days after dressing removal until the results of smears are obtained [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

“…All procedures were performed in the years 2019 to 2020 under general anesthesia according to the schemes described in previous publications [ 23 , 27 ], by one otosurgeon with many years of experience. The prospective study was approved by the Bioethical Committee of the Institute of Physiology and Pathology of Hearing, Warsaw, Poland (nr KB/17/2016).…”

Section: Methodsmentioning

confidence: 99%

Implantation of the Bonebridge BCI 602 after Mastoid Obliteration with S53P4 Bioactive Glass: A Safe Method of Treating Difficult Anatomical Conditions-Preliminary Results

Król

Cywka

Skarżyńska

et al. 2021

Life

View full text Add to dashboard Cite

This study presents the preliminary results of a new otosurgical method in patients after canal wall down (CWD) surgery; it involves the implantation of the Bonebridge BCI 602 implant after obliteration of the mastoid cavity with S53P4 bioactive glass. The study involved eight adult patients who had a history of chronic otitis media with cholesteatoma in one or both ears and who had had prior radical surgery. The mean follow-up period was 12 months, with routine follow-up visits according to the schedule. The analysis had two aspects: a surgical aspect in terms of healing, development of bacterial flora, the impact on the inner ear or labyrinth, recurrence of cholesteatoma, and possible postoperative complications (firstly, after obliteration of the mastoid cavity with S53P4 bioactive glass, then after implantation). The second was an audiological aspect which assessed audiometric results and the patient’s satisfaction based on questionnaires. During the follow-up period, we did not notice any serious postoperative complications. Studies demonstrated significantly improved hearing thresholds and speech recognition in quiet and noise using the Bonebridge BCI 602. Data collected after six months of use showed improved audiological thresholds and patient satisfaction. Based on the preliminary results, we believe that the proposed two-stage surgical method using bioactive glass S53P4 is a safe and effective way of implanting the Bonebridge BCI 602 in difficult anatomical conditions. This makes it possible to treat a larger group of patients with the device.

show abstract

Mastoid obliteration with S53P4 bioactive glass after canal wall down mastoidectomy: Preliminary results

Cited by 13 publications

References 36 publications

Evaluation of the Bonebridge BCI 602 active bone conductive implant in adults: efficacy and stability of audiological, surgical, and functional outcomes

Evaluation of the Bonebridge BCI 602 active bone conductive implant in adults: efficacy and stability of audiological, surgical, and functional outcomes

Postoperative surgical site infection in cholesteatoma surgery with and without mastoid obliteration, what can we learn?

Implantation of the Bonebridge BCI 602 after Mastoid Obliteration with S53P4 Bioactive Glass: A Safe Method of Treating Difficult Anatomical Conditions-Preliminary Results

Contact Info

Product

Resources

About